IROS and partners use Emirati Genome Programme to identify high-risk individuals before symptoms appear

Company secures first commercial product with data for active and chronic TED

No adverse events observed as study begins in EGFR‑mutant NSCLC

First immunotherapy approved for LACC in England offers new treatment option for women

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 […]

FDA alignment secured as company prepares to begin dosing in 2026

Breakwater phase 3 data show significant gains in progression‑free survival

Sanofi therapy becomes first disability‑targeting medicine for nrSPMS

Final draft guidance recommends D‑VRd on the NHS in England and Wales

Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial